BR9805597A - Associação em dose fixa de um inibidor da enzima conversora da angiotensina e de um antagonista dos canais de cálcio, procedimento para sua preparação e sua utilização para o tratamento de enfermidades cardiovasculares. - Google Patents

Associação em dose fixa de um inibidor da enzima conversora da angiotensina e de um antagonista dos canais de cálcio, procedimento para sua preparação e sua utilização para o tratamento de enfermidades cardiovasculares.

Info

Publication number
BR9805597A
BR9805597A BR9805597-6A BR9805597A BR9805597A BR 9805597 A BR9805597 A BR 9805597A BR 9805597 A BR9805597 A BR 9805597A BR 9805597 A BR9805597 A BR 9805597A
Authority
BR
Brazil
Prior art keywords
treatment
procedure
preparation
calcium channel
cardiovascular diseases
Prior art date
Application number
BR9805597-6A
Other languages
English (en)
Inventor
Pedro Canovas Soler
Joaquin Delgadillo Duarte
Luis Manuel Micheto Escude
Original Assignee
Vita Invest Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8299270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9805597(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vita Invest Sa filed Critical Vita Invest Sa
Publication of BR9805597A publication Critical patent/BR9805597A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: <B>"ASSOCIAçãO EM DOSE FIXA DE UM INIBIDOR DA ENZIMA CONVERSORA DA ANGIOTENSINA E DE UM ANTAGONISTA DOS CANAIS DE CáLCIO, PROCEDIMENTO PARA SUA PREPARAçãO E SUA UTILIZAçãO PARA O TRATAMENTO DE ENFERMIDADES CARDIOVASCULARES"<D>.Compreende (a) enalapirl ou um sal farmaceuticamente aceitável do mesmo e (b) nitrendipino ou um sal farmaceuticamente aceitável do mesmo, que se administra em forma galênica de dose unitária. O processo compreende: (a) dissolver enalapril em água com um sal inorgânico; b) misturar o nitrendipino com uma fração dos excipiente desagregantes, agente umidificante, diluente fragmentário, agente aglutinante e diluente plástico, previamente tamisados; c) granular a mistura do item (b) com a solução obtida no item (a); d) seca a massa granulada; e) incorporar o agente lubrificante e a fração restante de excipientes e homogeneizar o granulado calibrado; f) comprimir o granulado. Utilização da dita associação para a fabricação de um medicamento para tratamento de enfermidades do sistema cardiovascular.
BR9805597-6A 1997-05-13 1998-05-13 Associação em dose fixa de um inibidor da enzima conversora da angiotensina e de um antagonista dos canais de cálcio, procedimento para sua preparação e sua utilização para o tratamento de enfermidades cardiovasculares. BR9805597A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009701017A ES2125198B1 (es) 1997-05-13 1997-05-13 Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.

Publications (1)

Publication Number Publication Date
BR9805597A true BR9805597A (pt) 2000-04-11

Family

ID=8299270

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9805597-6A BR9805597A (pt) 1997-05-13 1998-05-13 Associação em dose fixa de um inibidor da enzima conversora da angiotensina e de um antagonista dos canais de cálcio, procedimento para sua preparação e sua utilização para o tratamento de enfermidades cardiovasculares.

Country Status (23)

Country Link
EP (1) EP0884054B9 (pt)
JP (1) JP3576806B2 (pt)
CN (1) CN1146418C (pt)
AR (1) AR011730A1 (pt)
AT (1) ATE236653T1 (pt)
AU (1) AU735404B2 (pt)
BR (1) BR9805597A (pt)
CA (1) CA2234899C (pt)
CZ (1) CZ292616B6 (pt)
DE (1) DE69813083T2 (pt)
DK (1) DK0884054T3 (pt)
ES (2) ES2125198B1 (pt)
HU (1) HUP9801075A3 (pt)
IL (1) IL124253A (pt)
NO (1) NO315545B1 (pt)
NZ (1) NZ330447A (pt)
PL (1) PL192117B1 (pt)
PT (1) PT884054E (pt)
RU (1) RU2182002C2 (pt)
SK (1) SK284337B6 (pt)
TR (1) TR199800847A2 (pt)
TW (1) TW562679B (pt)
ZA (1) ZA983806B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226950B1 (en) * 1999-11-03 2010-03-29 Richter Gedeon Nyrt The magnesium salt of enalapril and antihypertensive pharmaceutical composition containing it
EP1285655B1 (en) * 2000-04-11 2007-05-30 Sankyo Company, Limited Stabilized pharmaceutical compositions containing the calcium channel blocker azelnidipine
SK287988B6 (sk) * 2001-01-26 2012-09-03 Schering Corporation Composition, oral dosage form and use thereof
WO2004054574A1 (ja) * 2002-12-16 2004-07-01 Kissei Pharmaceutical Co., Ltd. 経口固形医薬
RU2618471C2 (ru) * 2012-12-03 2017-05-03 Закрытое Акционерное Общество "Вертекс" Пероральная фармацевтическая композиция диуретика и ингибитора АПФ в микронизированной форме, лекарственное средство и его применение
CN109350733A (zh) * 2018-06-08 2019-02-19 山东理工职业学院 一种马来酸依那普利片剂的制备方法
CN109985013B (zh) * 2019-05-10 2021-08-10 河北君圣药业有限公司 一种尼群地平分散片及其制备方法
CN115501224A (zh) * 2022-10-09 2022-12-23 南昌大学第一附属医院 马来酸依那普利叶酸片联合通心络在制备治疗高血压合并颈动脉硬化药物的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437917A1 (de) * 1984-10-17 1986-04-17 Bayer Ag, 5090 Leverkusen Kombination von dihydropyridinen mit ace-hemmern sowie ihre verwendung in arzneimitteln
USH734H (en) * 1988-03-07 1990-02-06 E. R. Squibb & Sons, Inc. Method for inhibiting onset of or treating migraine headaches employing an ACE inhibitor
JPH01275529A (ja) * 1988-03-21 1989-11-06 E R Squibb & Sons Inc 晩発性運動障害の抑制治療剤
CA2007525A1 (en) * 1989-01-30 1990-07-30 Zola P. Horovitz Method for facilating dieting employing an ace inhibitor
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
YU48602B (sh) * 1991-11-25 1998-12-23 Krka Tovarna Zdravil P.O. Postupak za dobijanje stabilne formulacije soli enalaprila
SI9300504A (en) * 1993-09-28 1995-04-30 Krka Process for preparation solid dispersions and deposits of calcium antagonist dihidropyrimidine derivates and pharmaceutical compositions comprising the same
US5573780A (en) * 1995-08-04 1996-11-12 Apotex Usa Inc. Stable solid formulation of enalapril salt and process for preparation thereof

Also Published As

Publication number Publication date
TR199800847A3 (tr) 1999-10-21
ATE236653T1 (de) 2003-04-15
CZ138198A3 (cs) 1998-12-16
CZ292616B6 (cs) 2003-11-12
TW562679B (en) 2003-11-21
CA2234899C (en) 2004-08-10
ES2197443T3 (es) 2004-01-01
NZ330447A (en) 1998-12-23
EP0884054A2 (en) 1998-12-16
DE69813083T2 (de) 2004-05-27
AR011730A1 (es) 2000-08-30
RU2182002C2 (ru) 2002-05-10
JPH11124330A (ja) 1999-05-11
AU735404B2 (en) 2001-07-05
EP0884054A3 (en) 2000-08-23
IL124253A (en) 2003-01-12
CN1212869A (zh) 1999-04-07
HU9801075D0 (en) 1998-07-28
ES2125198B1 (es) 1999-11-16
NO315545B1 (no) 2003-09-22
DK0884054T3 (da) 2003-07-21
DE69813083D1 (de) 2003-05-15
EP0884054B9 (en) 2007-02-14
CA2234899A1 (en) 1998-11-13
HUP9801075A2 (hu) 1999-01-28
SK61698A3 (en) 1998-12-02
HUP9801075A3 (en) 2000-12-28
SK284337B6 (sk) 2005-02-04
PT884054E (pt) 2003-08-29
PL326246A1 (en) 1998-11-23
AU6597398A (en) 1998-11-19
NO982112D0 (no) 1998-05-08
PL192117B1 (pl) 2006-09-29
JP3576806B2 (ja) 2004-10-13
EP0884054B1 (en) 2003-04-09
TR199800847A2 (xx) 1999-10-21
ZA983806B (en) 1999-02-19
CN1146418C (zh) 2004-04-21
NO982112L (no) 1998-11-16
ES2125198A1 (es) 1999-02-16

Similar Documents

Publication Publication Date Title
Fox et al. Approaching the golden age of natural product pharmaceuticals from venom libraries: an overview of toxins and toxin-derivatives currently involved in therapeutic or diagnostic applications
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
BR9915919A (pt) Proteìnas terapeuticamente ativas em plantas
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
DE69807634T2 (de) Medizinische einrichtung zur verabreichung von therapeutischen wirkstoffen
ATE175114T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
ATE314067T1 (de) Cannabinol-11-säurederivate als entzündungshemmer und analgetika
BR9805597A (pt) Associação em dose fixa de um inibidor da enzima conversora da angiotensina e de um antagonista dos canais de cálcio, procedimento para sua preparação e sua utilização para o tratamento de enfermidades cardiovasculares.
PT782449E (pt) Processo de fabrico de unidades de dosagem por granulacao humida
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
BR0001291A (pt) Desfolhante
MXPA05013392A (es) Composiciones farmaceuticas de atorvastatina.
DE69927147D1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69716586T2 (de) Gepufferte orthoesterpolymere enthaltende arzneimittel
BR9910130A (pt) Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação
WO2001017558A3 (en) Novel uses of mammalian ccr6 receptors and related reagents
WO2002070741A3 (en) Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
RU98109345A (ru) Сочетание ингибитора ангиотензин-превращающего фермента и антагониста кальциевых каналов с фиксированной дозой, способ ее изготовления и применение для лечения сердечно-сосудистых заболеваний
AR034435A1 (es) Agentes terapeuticos.
DE59909356D1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
RU2192248C2 (ru) Препарат &#34;антигриппин&#34;
EP1627927A3 (en) Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
BR0214301A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar doenças ou condições, para potencializar um efeito terapêutico de um agente do snc, para melhorar a memória recente de um paciente, para determinar a presença ou ausência de um receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, preparação farmacêutica acondicionada, e, uso de um composto ou sal
NO995004D0 (no) Anvendelse av bruskoligometrisk matriksprotein for behandling av reumatoid artritt
WO2000026362A3 (de) Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: LABORATORIOS VITA, S.A. (ES)

B25A Requested transfer of rights approved

Owner name: PROCTER AND GAMBLE PHARMACEUTICALS SARL (CH)

Free format text: TRANSFERIDO DE: LABORATORIOS VITA, S.A.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO APRESENTA REIVINDICACOES QUE NAO ATENDEM AO REQUISITO DE ATIVIDADE INVENTIVA ( ARTIGO 8O E ARTIGO 13 DA LEI 9279/)

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time